SCHEMBL26607166

SCHEMBL26607166

COc1cc(Cl)c(C(C)(Cl)C(F)(F)F)cc1C

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 5/20 0.33
MEN1 O00255 4/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NR3C1 P04150 6/20 0.32
NR3C2 P08235 6/20 0.32
MAPT P10636 2/20 0.32
NPSR1 Q6W5P4 1/20 0.32
ALDH1A1 P00352 3/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
POLB P06746 1/20 0.31
MAP3K14 Q99558 1/20 0.31
PGR P06401 2/20 0.31
TAAR1 Q96RJ0 1/20 0.31
GAA P10253 1/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26736860 0.85 GLA (0.34) GLATSHRKMT2AMEN1L3MBTL1
SCHEMBL167590 0.82 MAPT (0.40) KMT2AMEN1MAPTALDH1A1KDM4E
SCHEMBL26607082 0.82 NR3C1 (0.36) KMT2AMEN1NR3C1NR3C2MAPT
SCHEMBL26848529 0.80 NR3C1 (0.34) GLATSHRKMT2AMEN1L3MBTL1
SCHEMBL26607315 0.78 NR3C1 (0.33) GLATSHRKMT2AMEN1L3MBTL1
SCHEMBL26607162 0.75 TSHR (0.36) TSHRL3MBTL1NR3C1MAPTNPSR1
SCHEMBL26733406 0.75 HTR2A (0.41) KMT2AMEN1MAPTALDH1A1LMNA
SCHEMBL26607086 0.73 TSHR (0.32) TSHRMAPTNPSR1LMNA
SCHEMBL12706044 0.71 GAA (0.43) GLATSHRKMT2AMEN1L3MBTL1
SCHEMBL12805397 0.71 NR3C1 (0.44) KMT2AMEN1L3MBTL1NR3C1NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4511114-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 US disclosed
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED 2023-11-30 US disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205778-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382910-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN TRPV1, SCN3A, KCNN3 GLA 2939/4885TSHR 3347/4885KMT2A 3649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.